NT5E and colorectal cancer: Currently, a phase II trial (NCT06119217) is ongoing to assess the efficacy of TTX-030 combined with chemotherapy and budigalimab (an investigational anti-PD-1 antibody) in the treatment of metastatic PDAC, while the combination of oleclumab (anti-CD73 mAb) and durvalumab (anti-PD-1 mAb) has shown improved clinical responses in PDAC and advanced colorectal cancer [92].